New clinical and real-world data for Roche's Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss
Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema Real-world data reinforce that...
Source: marketscreener.com
